Topical Corticosteroids Page: 1 of 15

Total Page:16

File Type:pdf, Size:1020Kb

Topical Corticosteroids Page: 1 of 15 Federal Employee Program® 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.39 Section: Prescription Drugs Effective Date: October 1, 2020 Subsection: Topical Products Original Policy Date: January 1, 2020 Subject: Topical Corticosteroids Page: 1 of 15 Last Review Date: September 11, 2020 Topical Corticosteroids Description Locoid Cream, Lipocream, Lotion, Ointment, Alcovate Cream, Ointment 0.05% Solution 0.1% (alclometasone dipropionate) (hydrocortisone butyrate) Apexicon E Cream 0.05% Luxiq Foam 0.12% (diflorasone diacetate) (betamethasone valerate) Ala Scalp Lotion 2% Micort-HC Cream 2.5% (hydrocortisone) (hydrocortisone acetate) Capex Shampoo 0.01% Nolix Cream, Lotion 0.05% (fluocinolone acetonide) (flurandrenolide) Olux Foam 0.05% Cloderm Cream 0.10% Olux E Emulsion Foam 0.05% (clocortolone pivalate) (clobetasol propionate) Clobex Lotion, Shampoo, Spray 0.05% Pandel Cream 0.1% Clodan Shampoo 0.05% (hydrocortisone probutate) (clobetasol propionate) Cordran Cream 0.025% Cordran Cream, Lotion, Ointment 0.05% Psorcon Cream, Ointment 0.05% Cordran Tape 4mcg (diflorasone) (flurandrenolide) Cormax Solution 0.05% Sernivo Spray 0.05% (clobetasol propionate) (betamethasone dipropionate) Cutivate Cream, Lotion 0.05% Synalar Cream, Ointment, Solution 0.01% Cutivate Ointment 0.005% Synalar Cream, Ointment 0.025% (fluticasone propionate) (fluocinolone acetonide) 5.90.39 Section: Prescription Drugs Effective Date: October 1, 2020 Subsection: Topical Products Original Policy Date: January 1, 2020 Subject: Topical Corticosteroids Page: 2 of 15 Temovate-E Cream 0.05% Cyclocort Cream, lotion, Ointment 0.1% Temovate Cream, Gel, Ointment, Solution (amcinonide) 0.05% (clobetasol propionate) Derma-smooth /FS body oil 0.01% Texacort Solution 2.5% Derma-smooth /FS scalp oil 0.01% (hydrocortisone) (fluocinolone acetonide) Topicort Cream, Gel, Ointment, Spray Dermatop Cream, Ointment 0.1% 0.05% 0.25% (prednicarbate) (desoximetasone) Triamcinolone Cream, Lotion, Ointment, Desonate Gel 0.05% Spray 0.025%, 0.05%, 0.1%, 0.5% Desonide Cream Lotion, Ointment 0.05% Triderm Cream 0.1%, 0.5% Desowen Lotion 0.05% Kenalog aerosol spray 0.147 mg/ml (desonide) (triamcinolone acetonide) Diprosone Cream, Lotion, Ointment 0.05% Tridesilon Cream 0.05% Diprolene AF Cream, Gel, Lotion, Verdeso Foam 0.05% Ointment 0.05% (desonide) (betamethasone dipropionate) Trianex Ointment 0.05% Elocon Cream, Ointment, Solution 0.1% (triamcinolone acetonide) (mometasone furoate) Halog Cream, Ointment, Solution 0.1% Ultravate Cream, Lotion, Ointment 0.05% (halcinonide) (halobetasol propionate) Hydrocortisone Cream, Lotion, Ointment Wescort Cream, Ointment 0.2% 1%, 2.5% (hydrocortisone valerate) Impoyz Cream 0.025% Valisone Cream, Lotion, Ointment 0.01% (clobetasol proprionate) (betamethasone valerate) Lidex E Cream 0.05% Vanos Cream, Gel, Ointment, Solution 0.1% Lidex Gel, Ointment, Solution, Cream (fluocinonide) 0.05% (fluocinonide) Verdeso Foam 0.05% (desonide) Background 5.90.39 Section: Prescription Drugs Effective Date: October 1, 2020 Subsection: Topical Products Original Policy Date: January 1, 2020 Subject: Topical Corticosteroids Page: 3 of 15 The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Pharmacy topical products have the potential for misuse. Misuse of these topical products not just over the face but also for any skin problem is quite common. It is very important to inform people about the possible complications of these drugs and the extent of the problem because of irrational use of these drugs. The criteria was created in order to limit existing patients that have been taking doses above the FDA recommended limits and get them down to appropriate levels. This criteria is also intended to help prevent use of topical corticosteroids in topical foot baths (1-63). Regulatory Status FDA approved indication: (1-63) 1. Alclometasone dipropionate, amcinonide, betamethasone dipropionate, betamethasone valerate, clobetasol propionate, clocortolone pivalate, desonide, desoximetasone, diflorasone diacetate, fluocinolone acetonide, fluocinonide, flurandrenolide, fluticasone propionate, halcinonide, halobetasol propionate, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone probutate, hydrocortisone valerate, mometasone furoate, prednicarbate, triamcinolone acetonide are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses 2. Clobetasol Propionate Emollient Base Cream, Clobex Shampoo, Clobex Lotion, Clobex Spray, Derma-Smooth/FS (Scalp) Oil, Impoyz Cream, Olux Foam, Sernivo Spray, Topicort Spray, Ultravate Lotion are indicated for the treatment of psoriasis. 3. Cutivate Lotion, Derma-Smooth/FS (Body) Oil, Desonate Gel, Locoid Lipocream, Locoid Lotion, Verdeso Foam are indicated for the treatment of atopic dermatitis. 4. Capex Shampoo, Locoid Solution are indicated for the relief of the inflammatory and pruritic manifestations of seborrheic dermatitis. The approval quantity limit for all TCS is based on the average American Academy of Dermatology (AAD) estimation for twice daily dosing over 9% body surface area (BSA) for acute treatment and for maintenance therapy, taking into consideration the available package sizes across the TCS class. The three month limit will be 460gm or 460mL per month, which is 3 times the one month limit (59-63). 5.90.39 Section: Prescription Drugs Effective Date: October 1, 2020 Subsection: Topical Products Original Policy Date: January 1, 2020 Subject: Topical Corticosteroids Page: 4 of 15 Since manufacturer package sizes may vary, it is the discretion of the dispensing pharmacy to fill quantities up to these quantity limits. In such cases the filling limit and day supply may be less than what is indicated. For example, Pandel is available as an 80 gram tube, the initial limit is set at 460gm as a 90 day supply, therefore if dispensed as 240gm this may be considered less than a 90 day supply (59-63). Related policies Policy This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims. The topical products included in this policy may be considered medically necessary in patients with a FDA-approved indication supporting the use of topical product and if the conditions indicated below are met. The topical products included in this policy may be considered investigational in patients for all other indications. Prior-Approval Requirements Diagnosis Patient must have the following: FDA-approved indication supporting the use of topical product Prior – Approval Renewal Requirements None Policy Guidelines Pre - PA Allowance 5.90.39 Section: Prescription Drugs Effective Date: October 1, 2020 Subsection: Topical Products Original Policy Date: January 1, 2020 Subject: Topical Corticosteroids Page: 5 of 15 Quantity ALCLOMETASONE Strength UOM Potency 3 MONTH LIMIT DIPROPIONATE ALCLOMETASONE Low to 0.05% GM 460 CREAM medium ALCLOMETASONE Low to 0.05% GM 460 OINTMENT medium AMCINONIDE Strength UOM Potency 3 MONTH LIMIT AMCINONIDE 0.1% GM high 460 CREAM AMCINONIDE 0.1% ML high 460 LOTION AMCINONIDE 0.1% GM high 460 OINTMENT BETAMETHASONE Strength UOM Potency 3 MONTH LIMIT DIPROPIONATE SERNIVO 0.05% ML medium 460 SPRAY BETAMETHASONE DIPROPIONATE 0.05% GM medium 460 CREAM BETAMETHASONE DIPROPIONATE 0.05% ML medium 460 LOTION BETAMETHASONE DIPROPIONATE 0.05% GM very high 460 OINTMENT DIPROLENE AF 0.05% GM AUGMENTED CREAM high 460 BETAMETHASONE DIPROPIONATE 0.05% GM AUGMENTED CREAM BETAMETAMETHASONE DIPROPIONATE AUGMENTED 0.05% GM very high 460 GEL BETAMETAMETHASONE DIPROPIONATE AUGMENTED 0.05% ML very high 460 LOTION DIPROLENE 0.05% GM AUGMENTED OINTMENT very high 460 BETAMETHASONE DIPROPIONATE 0.05% GM AUGMENTED OINTMENT BETAMETHASONE Strength UOM Potency 3 MONTH LIMIT VALERATE BETAMETHASONE VALERATE 0.1% GM medium 460 CREAM LUXIQ 0.12% GM medium 460 AEROSOL FOAM 5.90.39 Section: Prescription Drugs Effective Date: October 1, 2020 Subsection: Topical Products Original Policy Date: January 1, 2020 Subject: Topical Corticosteroids Page: 6 of 15 BETAMETHASONE VALERATE 0.12% GM AEROSOL FOAM BETAMETHASONE VALERATE 0.1% ML medium 460 LOTION BETAMETHASONE VALERATE 0.1% GM medium 460 OINTMENT CLOBETASOL Strength UOM Potency 3 MONTH LIMIT PROPIONATE CLOBEX 0.05% ML SPRAY very high 460 CLOBETASOL 0.05% ML SPRAY CORMAX 0.05% ML SOLUTION high 460 TEMOVATE 0.05% ML SOLUTION IMPOYZ 0.025% GM high 460 CREAM TEMOVATE 0.05% GM CREAM very high 460 CLOBETASOL 0.05% GM CREAM OLUX 0.05% GM AEROSOL FOAM very high 460 CLOBETASOL 0.05% GM AEROSOL FOAM CLOBETASOL 0.05% GM very high 460 GEL CLOBEX 0.05% ML LOTION very high 460 CLOBETASOL 0.05% ML LOTION TEMOVATE 0.05% GM OINTMENT very high 460 CLOBETASOL 0.05% GM OINTMENT CLOBEX 0.05% ML SHAMPOO very high 460 CLODAN 0.05% ML SHAMPOO CLOBETASOL E 0.05% GM very high 460 EMOLLIENT CREAM OLUX-E 0.05% GM AEROSOL EMULSION FOAM very high 460 CLOBETASOL 0.05% GM AEROSOL EMULSION FOAM CLOCORTOLONE Strength UOM Potency 3 MONTH LIMIT PIVALATE 5.90.39 Section: Prescription Drugs Effective Date: October 1, 2020 Subsection: Topical Products Original Policy Date: January 1, 2020 Subject: Topical Corticosteroids Page: 7 of 15 CLODERM 0.10% GM CREAM medium 460 CLOCORTOLONE 0.10% GM CREAM DESONIDE Strength UOM Potency 3 MONTH LIMIT DESOWEN 0.05% GM CREAM Low to medium DESONIDE 0.05% GM CREAM
Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Medication List
    Medication List Walgreens Plus™ members receive discounts on thousands of generic and brand-name medications included on this Medication List, which is divided into two sections, “Value Priced” Medications and “Discounted” Medications*. The price for a medication identified as “Value-Priced” is listed below: Get savings up to 85% off Cash Prices • 30-day-supply drugs cost $5 (tier 1), $10 (tier 2) or $15 (tier 3) on Atorvastatin (generic Lipitor) and • 90-day-supply drugs cost $10 (tier 1), $20 (tier 2) or $30 (tier 3) Rosuvastatin (generic Crestor) †† The Discounted Medications section lists the discounts offered to Walgreens Plus members on other generic and brand-name medications not included in the Value-Priced Medication section. The price for a medication is based on its tier and whether it is a 30-day or 90-day supply†. There may be an additional cost for quanities greater than those listed. This discount prescription pricing applies only to Walgreen Plus members on prescriptions purchased in select Walgreens stores that are not billed to insurance and/or used in combination with other health or pharmacy benefit programs. For further details, see your pharmacist or Walgreens.com/Plus. VALUE GENERICS NAPROXEN 250MG TAB 2 60 180 Antifungal NAPROXEN 500MG TAB 2 60 180 Quantity NAPROXEN 375MG TAB 2 60 180 Drug Name Tier 30 90 NAPROXEN DR 500MG TAB 3 60 180 FLUCONAZOLE 150MG TAB 2 1 3 TERBINAFINE 250MG TAB 2 30 90 Asthma Quantity Antiviral Drug Name Tier 30 90 Quantity ALBUTEROL 0.083% INH SOLN 25X3ML 2 75 225 Drug Name Tier 30 90 AMINOPHYLLINE
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Drugs That Are Not Covered
    Drugs that are Not Covered* Current 10/1/21 In addition to this list, newly marketed prescription medications may not be covered until the Pharmacy & Therapeutics Committee has had an opportunity to review the medication, to determine whether the medication will be covered and if so, which tier will apply based on safety, efficacy and the availability of other products within that class of medications. The current list of newly marketed drugs can be found on our New to Market Drug list. Abilify tablets albuterol HFA inhalers (authorized Apexicon E cream Abilify MyCite tablets generics for ProAir, Proventil, Ventolin Apidra vials Absorica capsules HFA inhalers) Apidra SoloStar injection Absorica LD capsules Aldactone tablets Aplenzin tablets Abstral sublingual tablets Aldara cream Apriso capsules Acanya gel and pump gel Alkindi sprinkle capsules Arava tablets Accupril tablets Allegra Children’s Allergy ODT Arazlo lotion acetaminophen 320.5 mg/caffeine 30 Allegra ODT, suspension and tablets Arestin microspheres mg/dihydrocodeine 16 mg Alltizal tablets Aricept tablets capsulesAciphex tablets alogliptin (authorized generic for Aricept ODT Aciphex Sprinkle capsules Nesina) Arimidex tablets Acticlate tablets alogliptin/metformin tablets (authorized Arixtra injection Active-Prep kits generic for Kazano) ArmonAir Digihaler inhaler Activella tablets alogliptin/pioglitazone (authorized ArmonAir Respiclick inhaler Actonel tablets generic for Oseni) Aromasin tablets Actoplus Met tablets Alphagan P 0.1% eye drops Arthrotec 50 and 75 tablets Actos
    [Show full text]
  • A List of Medications That May Lower Your Patients' Costs
    A list of medications that may lower your patients’ costs INTRODUCTION Catamaran utilizes a Pharmacy and Therapeutics Committee (P & T Committee), made up of practicing physicians, pharmacists, and nurses to help ensure that our formulary is medically sound and that it supports patient health. This committee reviews and evaluates medications on the formulary based on safety and efficacy to help maintain clinical integrity in all therapeutic categories. FORMULARY DESIGN There are numerous formulary designs that can be used by a pharmacy benefits administrator. Catamaran has chosen a formulary structure which is open and incentive based. Open Formulary: features co‐payments for medications that are preferred and non‐ preferred brands, plus lower co‐payments for generic drugs. Incentive Based: features different co‐payments for medications that are on or off the formulary. In this type of formulary, the patient cost structure may be two‐tier, three‐ tier, or four‐tier design. USING THIS FORMULARY REFERENCE GUIDE TO HELP CONTAIN COSTS Many benefit sponsors use the Catamaran formulary to help manage the overall cost of providing prescription drug benefits. This formulary offers a wide range of medications from which to choose. We realize that this formulary reference guide may not include every drug from every manufacturer. However, choosing a preferred drug when it is appropriate can provide access to the necessary medications to stay healthy, at a cost that is more affordable. KNOWING HOW THE FORMULARY INFORMATION IS ORGANIZED The following formulary reference guide is designed so that generic products are listed first in each drug category. The preferred brand name products are listed next, and non‐preferred brand products are listed last.
    [Show full text]
  • Product Monograph Cyclocort
    PRODUCT MONOGRAPH PrCYCLOCORT® amcinonide USP Cream, USP 0.1% w/w Ointment, USP 0.1% w/w Lotion 0.1% w/w Topical Corticosteroid GlaxoSmithKline Inc. Date of Revision: 7333 Mississauga Road November 4, 2014 Mississauga, Ontario L5N 6L4 www.stiefel.ca Submission Control No: 175944 ©2014 GlaxoSmithKline Inc., All Rights Reserved ®CYCLOCORT is a registered trade-mark owned by GlaxoSmithKline Inc. November 4, 2014 Page 1 of 17 TABLE OF CONTENTS PAGE PART I: HEALTH PROFESSIONAL INFORMATION.................................................. 3 SUMMARY PRODUCT INFORMATION ................................................................... 3 INDICATIONS AND CLINICAL USE ......................................................................... 3 CONTRAINDICATIONS .............................................................................................. 3 WARNINGS AND PRECAUTIONS ............................................................................. 4 ADVERSE REACTIONS ............................................................................................... 8 DRUG INTERACTIONS ............................................................................................... 8 DOSAGE AND ADMINISTRATION ........................................................................... 9 OVERDOSAGE ........................................................................................................... 11 STORAGE AND STABILITY ..................................................................................... 11 SPECIAL HANDLING INSTRUCTIONS
    [Show full text]
  • Dry Skin Eczema
    Dry Skin/Eczema 1. Avoid irritating factors in soaps, detergents, fabric softeners, dryer sheets, dyes, or perfumes. Be sure all products are scent and dye free (read labels!). Examples Include: Detergent – All Free & Clear, Dreft Skin Cleanser – Cetaphil, CeraVe Hydrating Cleanser, Aquaphor (wash), Aveeno Eczema Wash Moisturizer – Vaseline, Aquaphor, CeraVe, Cetaphil Restoraderm, Aveeno Eczema Cream, or even some natural oils (i.e. coconut oil, however keep in mind some may be allergic to this) 2. Give a SHORT daily lukewarm bath of 5-10 minutes with a mild skin cleanser. Don’t rub with a washcloth – this can lead to irritation. Remember that water is actually drying to our skin (it can remove the essential oils that protect us from dryness). 3. Immediately after the bath, pat the child relatively dry, then apply ointment or cream generously from head to toe. In children with eczema, one of the most important steps in their care is using moisturizers; this must be done multiple times every day for best results. 4. When the child is itchy/scratching give Claritin (OTC) or Zyrtec (OTC) in the morning and give Benadryl (OTC) or Atarax (Prescription) at night. 5. Trim nails on a regular basis to minimize scratch injury. Put gloves on at night for severe scratches. 6. Remember that eczema is a chronic condition and will come and go for several months/years. Our goal is to get it under control, but the child who has this predisposition will probably always need a little “extra moisture” and skin care. Also, getting viral infections or fevers or other illnesses as well changes in weather or certain foods might precipitate an outbreak of eczema temporarily.
    [Show full text]
  • Choosing Topical Corticosteroids JONATHAN D
    Choosing Topical Corticosteroids JONATHAN D. FERENCE, PharmD, Nesbitt College of Pharmacy and Nursing, Wilkes University, Wilkes-Barre, Pennsylvania ALLEN R. LAST, MD, MPH, Racine Family Medicine Residency Program, Medical College of Wisconsin, Racine, Wisconsin Topical corticosteroids are one of the oldest and most useful treatments for dermatologic conditions. There are many topical steroids available, and they differ in potency and formulation. Successful treatment depends on an accurate diagnosis and consideration of the steroid’s delivery vehicle, potency, frequency of application, duration of treatment, and side effects. Although use of topical steroids is common, evidence of effectiveness exists only for select condi- tions, such as psoriasis, vitiligo, eczema, atopic dermatitis, phimosis, acute radiation dermatitis, and lichen sclero- sus. Evidence is limited for use in melasma, chronic idiopathic urticaria, and alopecia areata. (Am Fam Physician. 2009;79(2):135-140. Copyright © 2009 American Academy of Family Physicians.) opical steroids are available in a Indications variety of potencies and prepara- An accurate diagnosis is essential when tions. Physicians should become selecting a steroid. A skin scraping and familiar with one or two agents in potassium hydroxide test can clarify whether T each category of potency to safely and effec- a steroid or an antifungal is an appropriate tively treat steroid-responsive skin condi- choice, because steroids can exacerbate a tions. When prescribing topical steroids, fungal infection. Topical corticosteroids are it is important to consider the diagnosis effective for conditions that are character- as well as steroid potency, delivery vehicle, ized by hyperproliferation, inflammation, frequency of administration, duration of and immunologic involvement. They can treatment, and side effects.
    [Show full text]
  • Adverse Effects of Topical Corticosteroids in Paediatric Eczema: Australasian Consensus Statement
    PEER REVIEWED FEATURE Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement Emma Mooney,1 Marius Rademaker,2 Rebecca Dailey,3 Ben S. Daniel,1 Catherine Drummond,4,18 Gayle Fischer,5,13 Rachael Foster,6 Claire Grills,1 Anne Halbert,6 Sarah Hill,2 Emma King,1 Elizabeth Leins,1 Vanessa Morgan,1,7 Roderic J. Phillips,8,9,16 John Relic,10 Michelle Rodrigues,1,11 Laura Scardamaglia,1,3,7,12 Saxon Smith,5,13 John Su,1,3,14,15,16 Orli Wargon17 and David Orchard1 Reproduced from the Australasian Journal of Dermatology 2015; 56(4): 241-251 with the permission of the authors, the Australasian College of Dermatologists and the publisher Wiley Publishing Asia Pty Ltd. © 2015 The Australasian College of Dermatologists. MedicineToday 2015; 16(12): 40-50 ABSTRACT 1 9 Department of Paediatric Dermatology, Department of Vascular Biology, Atopic eczema is a chronic inflammatory disease affecting about Royal Children’s Hospital, 3University of Melbourne, 7Department of 30% of Australian and New Zealand children. Severe eczema Dermatology, Royal Melbourne Hospital, 8Department of Paediatrics, Monash costs over AUD 6000/year per child in direct medical, hospital University, 15Monash University, 11Department of Dermatology, St Vincent’s and treatment costs as well as time off work for care givers and Hospital, 12Department of Dermatology, Western Hospital, 14Department of untold distress for the family unit. In addition, it has a negative Dermatology, Eastern Health, 16Murdoch Children’s Research Institute, impact on a child’s sleep, education, development and self Melbourne, Victoria, 4Department of Dermatology, Canberra Hospital, esteem.
    [Show full text]
  • Prior Authorization PDL Implementation Schedule
    Prior Authorization PDL Implementation Schedule Effective Date: Item January 1, 2017 – Descriptive Therapeutic Class Drugs on PDL Drugs which Require PA Nbr Updated: March 1, 2018 1 ADD/ADHD Amphetamine Salt Combo Tablet ( Generic Adderall®) Amphetamine ODT (Adzenys® XR ODT) Stimulants and Related Agents Amphetamine Salt Combo ER (Adderall XR®) Amphetamine Suspension (Dyanavel XR®) Atomoxetine Capsule (Strattera®) Amphetamine Salt Combo ER (Generic; Authorized Generic for Adderall XR) Dexmethylphenidate (Generic; Authorized Generic of Focalin®) Amphetamine Sulfate Tablet (Evekeo®) Dexmethylphenidate ER (Focalin XR®) Armodafinil Tablet (Generic; Authorized Generic; Nuvigil®) Dextroamphetamine Solution (Procentra®) Clonidine ER Tablet (Generic; Kapvay®) Dextroamphetamine Sulfate Tablet (Generic) Dexmethylphenidate (Focalin®) Guanfacine ER Tablet (Generic) Dexmethylphenidate XR (Generic; Authorized Generic for Focalin XR) Lisdexamfetamine Capsule (Vyvanse®) Dextroamphetamine Sulfate Capsule ER (Generic; Dexedrine®Spansule) Methylphenidate IR (Generic) Dextroamphetamine IR Tablet (Zenzedi®) Methylphenidate ER Chew (Quillichew ER®) Dextroamphetamine Solution (Generic for Procentra®) Methylphenidate ER Capsule (Metadate CD®) Guanfacine ER Tablet (Intuniv®) Methylphenidate ER Tablet (Generic; Generic Concerta®; Methamphetamine (Generic; Desoxyn®) Authorized Generic Concerta®) Methylphenidate ER Susp (Quillivant XR®) Methylphenidate IR (Ritalin®) Modafinil Tablet (Generic) Methylphenidate Solution (Generic; Authorized Generic; Methylin®) Methylphenidate
    [Show full text]
  • Steroids Topical
    Steroids, Topical Therapeutic Class Review (TCR) October 3, 2017 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. October
    [Show full text]